TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05752786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Less Meat Challenge
Description: Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Eat Less Meat Challenge
Description: Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
Study: NCT05984810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
Description: Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
Study: NCT06165380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardenilimab Combined With Chemotherapy
Description: Cardenilimab Combined With Chemotherapy
Study: NCT05955079

Intervention type: OTHER
Intervention: Whole blood
Description: 3 samples (before, after surgery and before chemotherapy)
Study: NCT05431569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MW3211
Description: 6MW3211 injection ,30mg/kg,iv drip，Q2W
Study: NCT04373785

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG101m
Description: Oral NG101m capsule continuously twice daily.
Study: NCT05603754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorecivivint
Description: One intra-articular injection of 0.07 mg lorecivivint in 2 mL vehicle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
Study: NCT05594368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)
Description: Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.
Study: NCT05913466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid group
Description: Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
Study: NCT05289856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Avelumab and Cabozantinib
Description: Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months
Study: NCT05913466

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water group
Description: This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
Study: NCT05550883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The patients in this group participated in aerobic exercise training for 45 minutes, three sessions per week for 6 weeks. They underwent the proper warm up to minimize the risk of musculoskeletal injury .The training session started by a proper warm up for 5 min in the form of mild stretching for the involved muscle group to prepare the exercised muscles and improve blood supply for skeletal muscle to prevent fatigue or injury. Patients in this study group performed aerobic exercise (in the form of treadmill training) All sessions were supervised to ensure correct technique and monitor the appropriate amount of exercise. The training session ended by a proper cooling down for 5 min to prevent fatigue or injury.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibromyalgia Agents
Description: tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibromyalgia Agents
Description: tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
Study: NCT05726461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AndroidAPS-rt-CGM;
Description: Insulin therapy (aspart, lispro or glulisine) with AndroidAPS-rt-CGM.AndroidAPS-rt-CGM consists of three components:1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sensor augmented pump(SAP);
Description: Insulin therapy (aspart, lispro or glulisine) with sensor augmented pump(SAP).SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
Study: NCT04565613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral protein supplementation
Description: The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.~Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue.
Study: NCT04776564

Intervention type: OTHER
Intervention: Participation in the couple enhancement program
Description: Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)

Intervention type: OTHER
Intervention: Participation in the couple enhancement program
Description: Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)

Intervention type: OTHER
Intervention: Participation in the couple enhancement program
Description: Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)

Intervention type: OTHER
Intervention: Participation in the couple enhancement program
Description: Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)

Intervention type: OTHER
Intervention: Participation in the couple enhancement program
Description: Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)

Intervention type: OTHER
Intervention: Participation in the couple enhancement program
Description: Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)
Study: NCT05445518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jump Start Plus COVID Support
Description: The Jump Start Plus COVID Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
Study: NCT05701553

Intervention type: DRUG
Intervention: Anti-PD-1/PD-L1
Description: Intravenous injection at indicated dose for at least 6 months

Intervention type: DRUG
Intervention: S-Adenosyl-Methionine
Description: Taken orally at indicated dose for at least 6 months
Study: NCT05851885

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI-based reporting system
Description: AI-based reporting system is a software platform for real-time analysis and records of abnormalities and landmarks during endoscopy.
Study: NCT04414553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Active and Healthy Families
Description: Community-AHF will consist of eight, semimonthly 2-hour group appointments. Community-AHF sessions will target two areas: 1) Practical information regarding importance of healthy behaviors, and 2) Problem-solving skills to overcome barriers to improving diet and increasing physical activity and other related healthy behaviors. Each session covers specific objectives, includes a number of complementary activities and provides participants with take-home materials to facilitate behavior change.~Community-AHF will be delivered by a nurse and a Community Health Worker (CHW) trained by a consultant nutritionist and study investigators. The CHW will contact families between group sessions to discuss challenges and successes regarding lifestyle changes.
Study: NCT05850442

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionary
Description: Patients will be asked to fill Fibromyalgia Impact Questionary, WHO Short Quality of Life Questionary, McGill Pain Questionary and Beck Anxiety Questionary
Study: NCT04966234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 100 MG [Noxafil]
Description: Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 40 MG/ML
Description: Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile
Study: NCT05710250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-week MBSR program
Description: Participants will follow a 6-week program of mindfulness meditation. MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 6 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6-week muscular relaxation program
Description: Control group : This group will follow a 6-week program of progressive muscle relaxation training in order to learn achieving a deep relaxation of the body through voluntary tensing and relaxing muscles. It proceeds by the individual sequentially tensing and then releasing specific groups of muscles throughout the body, and noticing how tension feels relative to relaxation.~The accomplishment of physical relaxation promotes mental calmness in a parallel manner. This program is based on the work of Bernstein and Borkovec and Jacobson, and will be structured in 6-week group with weekly two and half hours sessions and out-of-session assignments for at-home practice (30-min daily).
Study: NCT06159283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulins
Description: Dosage is Immunoglobulin 1,000mg/kg IV. It administer over 2\~3 days.
Study: NCT00057057

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Care
Study: NCT05445518

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Caregivers-Healthy Children (HC2)
Description: The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom.
Study: NCT06094309

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin type A injection
Description: The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A injection
Description: The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.
Study: NCT05110781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT05287243

Intervention type: OTHER
Group type: OTHER
Intervention: inspiratory muscle training
Description: Participants will complete inspiratory muscle training daily in their homes for 12 weeks. The dosage will depend on their initial maximum pressure. At the end of the 12 week intensive period, participants will reduce the inspiratory resistance by a third and continue a maintenance training for an additional 12 weeks.
Study: NCT05171972

Intervention type: DRUG
Intervention: Ofatumumab
Description: This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
Study: NCT06446518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure
Description: Assessing immersive virtual reality as a distraction tool in anxiolysis and pain modulation.
Study: NCT05831527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARMRA™ Bovine Colostrum
Description: Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARMRA™ Bovine Colostrum
Description: Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks.
Study: NCT05402254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacovigilance Program
Description: Knowledge of the risks in the use of the drug, identification and notification of ADE
Study: NCT06351826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELLASI
Description: A structured intervention for polytrauma patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Unstructured interventions that are given in everyday practice (standard intervention)
Study: NCT05229991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
Study: NCT05370365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Below elbow cast
Description: Patients will be stay with a below elbow cast for 4 or 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Below elbow cast
Description: Patients will be stay with a below elbow cast for 4 or 6 weeks
Study: NCT06337981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (AJU-S56 5% and placebo)
Description: (AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-S56 5%
Description: (AJU-S56 5%), 1drop/1times, 6times in a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(Vehicle)
Description: Placebo(Vehicle), 1drop/1times, 6times in a day
Study: NCT05881707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D064, D702
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D064, D702
Description: QD, PO
Study: NCT04883255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Δ9-tetrahydrocannabinol (THC)
Description: 5-day course of orally-administered THC (dronabinol), 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Δ9-tetrahydrocannabinol (THC)
Description: 5-day course of orally-administered THC (dronabinol), 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg cannabidiol (CBD)
Description: 5-day course of orally-administered CBD, 600 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 600 mg cannabidiol (CBD)
Description: 5-day course of orally-administered CBD, 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5-day course of orally-administered placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5-day course of orally-administered placebo
Study: NCT04795401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRAME FR IFU
Description: The surgeon will use the medical device FRAME to perform the plication procedure. The device will be selected and implanted according to the product IFU.
Study: NCT05809427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Periodontal probing
Description: Imaging/Scanning and recording : Ultrasonic periodontal probing per operator (10 teeth X 6 sites/teeth = 60 probing sites per operator). In addition, 2 teeth per patient will be probed with the ultrasonic probe a second time (2 teeth x 6 sites per tooth = 12 sites per patient) for intra-operator reproducibility purpose.~Manual probing per operator with the OMS probe (part of the routine of care)
Study: NCT05406128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preoperative erector spina plane block
Description: Erector spina plane block will be applied to preoperative group patients in the preoperative period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative erector spina plane block
Description: In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
Study: NCT06184191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic hand rehabilitation
Description: Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic hand rehabilitation
Description: Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic hand rehabilitation
Description: Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.